ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicAdvances and Challenges in Cancer ImmunotherapyView all articles
Meta-Analysis of Tuberculosis Incidence and Risk in Cancer Patients Treated with Immune Checkpoint Inhibitors
Provisionally accepted
- Huangshi Central Hospital, Huangshi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To systematically evaluate the incidence of tuberculosis (TB) in cancer patients treated with immune checkpoint inhibitors (ICIs) and compare the risk of TB between ICI-treated and non-ICI-treated cancer patients, so as to provide evidence-based support for TB prevention and control in cancer patients undergoing ICI therapy. Methods: We searched the English databases including PubMed, Embase, and Cochrane Library from their inception to April 2025 for cohort studies or case-control studies that reported TB occurrence in cancer patients after ICI treatment or compared TB risk between ICI-treated and non-ICI-treated groups. Two independent researchers conducted literature screening, data extraction, and quality assessment using the Newcastle-Ottawa Scale (NOS) or Cochrane Risk of Bias Tool. Meta-analysis was performed using RevMan 5.4 and Stata 16.0 software. The pooled incidence of TB with 95% confidence interval (95%CI) in ICI-treated cancer patients was calculated; the relative risk (RR) with 95%CI was pooled to compare TB risk between the ICI and non-ICI groups. Funnel plots and Egger's test were used to assess publication bias. Results: A total of 10 studies were included, involving 10,196 cancer patients in the ICI group and 147,528 cancer patients in the non-ICI group. Meta-analysis results showed that: ①The pooled incidence of TB in cancer patients after ICI treatment was 0.63% (95%CI: 0.47%, 0.80%); ② There was no significant difference in TB risk between the ICI group and the non-ICI group (pooled RR=3.16, 95%CI: 0.44, 22.64, P=0.138), with substantial heterogeneity (I ² =97.1%, P<0.001). Subsequent subgroup analysis revealed that a history of TB was a critical effect modifier, with TB risk significantly elevated in the ICI group only among studies that included patients with prior TB (RR=7.32, 95%CI:1.19, 45.12). Conclusion: Current evidence indicates that in the overall cancer population, ICI treatment was not associated with a significantly increased risk of TB compared to non-ICI regimens. Importantly, patients with a history of prior TB were found to be at significantly higher risk. This highlights the critical need for enhanced TB screening and vigilant monitoring, especially in this vulnerable subgroup, to mitigate TB-related adverse outcomes.
Keywords: Cancer, immune checkpoint inhibitors, Incidence, Morbidity risk, Tuberculosis
Received: 13 Oct 2025; Accepted: 11 Feb 2026.
Copyright: © 2026 Ming, Chen, Fu, Hu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wenbing Hu
Hui Yu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.